Atossa Genetics Inc. (ATOS) Sets All-Time Low

June 29, 2018 - By Nellie Deboer

Atossa Genetics Inc. (NASDAQ:ATOS) Corporate Logo

Atossa Genetics Inc. (NASDAQ:ATOS) touched all time low on Jun, 29 touching $2.21. Our target is $2.06. Barchart.com announced it. The company has $6.22 million market cap. The company’s valuation will be $435,470 less at $2.06 target.

ATOS is hitting $2.21 during the last trading session, after decreased 3.07%.Currently Atossa Genetics Inc. is downtrending after 41.40% change in last June 29, 2017. ATOS has also 123,725 shares volume. ATOS underperformed by 53.97% the S&P500.

Atossa Genetics Inc. (NASDAQ:ATOS)’s earnings report is anticipated on August, 13., according to RTT. Analysts have expectation on stock’s EPS of $-0.74. That’s up 90.36 % from last year’s $-7.68 EPS. After $-0.71 EPS was announced last quarter, analysts now see negative EPS growth of 4.23 % for Atossa Genetics Inc..

Atossa Genetics Inc. (NASDAQ:ATOS) Ratings Coverage

Total analysts of 2 have positions in Atossa Genetics (NASDAQ:ATOS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 26, 2018 according to StockzIntelligence Inc Atossa Genetics has 2 analyst reports. On Friday, January 26 the firm earned “Buy” rating by Maxim Group.

For more Atossa Genetics Inc. (NASDAQ:ATOS) news brought out recently go to: Seekingalpha.com, Benzinga.com, Benzinga.com, Nasdaq.com or Streetinsider.com. The titles are as follows: “Your Daily Pharma Scoop: Reata Begins New Trial, CytoDyn Amends Protocol, Argenx Reports Positive Data” brought out on June 22, 2018, “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” on June 15, 2018, “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” with a publish date: June 29, 2018, “Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board” and the last “Atossa Genetics (ATOS) Announces Opening of Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast …” with publication date: June 26, 2018.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States.The firm is worth $6.22 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions.Currently it has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: